179 related articles for article (PubMed ID: 38348398)
21. Engineering the probiotic bacterium Escherichia coli Nissle 1917 as an efficient cell factory for heparosan biosynthesis.
Hu S; Zhao L; Hu L; Xi X; Zhang Y; Wang Y; Chen J; Chen J; Kang Z
Enzyme Microb Technol; 2022 Aug; 158():110038. PubMed ID: 35453037
[TBL] [Abstract][Full Text] [Related]
22. Split immune response after oral vaccination of mice with recombinant Escherichia coli Nissle 1917 expressing fimbrial adhesin K88.
Remer KA; Bartrow M; Roeger B; Moll H; Sonnenborn U; Oelschlaeger TA
Int J Med Microbiol; 2009 Nov; 299(7):467-78. PubMed ID: 19467927
[TBL] [Abstract][Full Text] [Related]
23. High density fermentation of probiotic E. coli Nissle 1917 towards heparosan production, characterization, and modification.
Datta P; Fu L; Brodfuerer P; Dordick JS; Linhardt RJ
Appl Microbiol Biotechnol; 2021 Feb; 105(3):1051-1062. PubMed ID: 33481068
[TBL] [Abstract][Full Text] [Related]
24. Construction of recombinant E. coli Nissle 1917 (EcN) strains for the expression and secretion of defensins.
Seo EJ; Weibel S; Wehkamp J; Oelschlaeger TA
Int J Med Microbiol; 2012 Nov; 302(6):276-87. PubMed ID: 22748509
[TBL] [Abstract][Full Text] [Related]
25. K5 Capsule and Lipopolysaccharide Are Important in Resistance to T4 Phage Attack in Probiotic
Soundararajan M; von Bünau R; Oelschlaeger TA
Front Microbiol; 2019; 10():2783. PubMed ID: 31849915
[TBL] [Abstract][Full Text] [Related]
26. Two New Plasmid Post-segregational Killing Mechanisms for the Implementation of Synthetic Gene Networks in Escherichia coli.
Fedorec AJH; Ozdemir T; Doshi A; Ho YK; Rosa L; Rutter J; Velazquez O; Pinheiro VB; Danino T; Barnes CP
iScience; 2019 Apr; 14():323-334. PubMed ID: 30954530
[TBL] [Abstract][Full Text] [Related]
27. Probiotic Escherichia coli Nissle 1917 reduces growth, Shiga toxin expression, release and thus cytotoxicity of enterohemorrhagic Escherichia coli.
Mohsin M; Guenther S; Schierack P; Tedin K; Wieler LH
Int J Med Microbiol; 2015 Jan; 305(1):20-6. PubMed ID: 25465158
[TBL] [Abstract][Full Text] [Related]
28. Tumor Colonization and Therapy by
Gentschev I; Petrov I; Ye M; Kafuri Cifuentes L; Toews R; Cecil A; Oelschaeger TA; Szalay AA
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551519
[TBL] [Abstract][Full Text] [Related]
29. Escherichia coli Nissle 1917 secondary metabolism: aryl polyene biosynthesis and phosphopantetheinyl transferase crosstalk.
Jones CV; Jarboe BG; Majer HM; Ma AT; Beld J
Appl Microbiol Biotechnol; 2021 Oct; 105(20):7785-7799. PubMed ID: 34546406
[TBL] [Abstract][Full Text] [Related]
30. Probiotic Escherichia coli Nissle 1917 propelled micro-robot with pH sensitivity for hypoxia targeted intestinal tumor therapy.
Wang T; Yin Q; Huang HY; Wang Z; Song H; Luo X
Colloids Surf B Biointerfaces; 2023 May; 225():113277. PubMed ID: 36996630
[TBL] [Abstract][Full Text] [Related]
31. Recombinant production of omega-3 fatty acids by probiotic Escherichia coli Nissle 1917.
Amiri-Jami M; Abdelhamid AG; Hazaa M; Kakuda Y; Griffths MW
FEMS Microbiol Lett; 2015 Oct; 362(20):. PubMed ID: 26371149
[TBL] [Abstract][Full Text] [Related]
32. Development of probiotic E. coli Nissle 1917 for β-alanine production by using protein and metabolic engineering.
Hu S; Fei M; Fu B; Yu M; Yuan P; Tang B; Yang H; Sun D
Appl Microbiol Biotechnol; 2023 Apr; 107(7-8):2277-2288. PubMed ID: 36929190
[TBL] [Abstract][Full Text] [Related]
33. Green fluorescent protein for detection of the probiotic microorganism Escherichia coli strain Nissle 1917 (EcN) in vivo.
Schultz M; Watzl S; Oelschlaeger TA; Rath HC; Göttl C; Lehn N; Schölmerich J; Linde HJ
J Microbiol Methods; 2005 Jun; 61(3):389-98. PubMed ID: 15767015
[TBL] [Abstract][Full Text] [Related]
34. The Probiotic
Bury S; Soundararajan M; Bharti R; von Bünau R; Förstner KU; Oelschlaeger TA
Front Microbiol; 2018; 9():929. PubMed ID: 29896160
[TBL] [Abstract][Full Text] [Related]
35. Spreading Advantages of Coresident Plasmids
He K; Li W; Zhao B; Xu H; Pan Y; He D; Hu G; Wu H; Yuan L
Microbiol Spectr; 2022 Feb; 10(1):e0170621. PubMed ID: 35171014
[TBL] [Abstract][Full Text] [Related]
36. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium.
Wehkamp J; Harder J; Wehkamp K; Wehkamp-von Meissner B; Schlee M; Enders C; Sonnenborn U; Nuding S; Bengmark S; Fellermann K; Schröder JM; Stange EF
Infect Immun; 2004 Oct; 72(10):5750-8. PubMed ID: 15385474
[TBL] [Abstract][Full Text] [Related]
37. Gene Amplification Uncovers Large Previously Unrecognized Cryptic Antibiotic Resistance Potential in E. coli.
Suarez SA; Martiny AC
Microbiol Spectr; 2021 Dec; 9(3):e0028921. PubMed ID: 34756069
[TBL] [Abstract][Full Text] [Related]
38. High-quality genome-scale metabolic network reconstruction of probiotic bacterium Escherichia coli Nissle 1917.
van 't Hof M; Mohite OS; Monk JM; Weber T; Palsson BO; Sommer MOA
BMC Bioinformatics; 2022 Dec; 23(1):566. PubMed ID: 36585633
[TBL] [Abstract][Full Text] [Related]
39. FabV/Triclosan Is an Antibiotic-Free and Cost-Effective Selection System for Efficient Maintenance of High and Medium-Copy Number Plasmids in Escherichia coli.
Ali SA; Chew YW
PLoS One; 2015; 10(6):e0129547. PubMed ID: 26057251
[TBL] [Abstract][Full Text] [Related]
40. Biosynthesis of phenylpyruvic acid from l-phenylalanine using chromosomally engineered Escherichia coli.
Xiong T; Bai Y; Fan TP; Zheng X; Cai Y
Biotechnol Appl Biochem; 2022 Oct; 69(5):1909-1916. PubMed ID: 34554609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
